Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Acasti Pharma News

    2,64 € 0,00% +0,00 €
    08:05:48 Uhr Frankfurt aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A3EP78
    ISIN: CA00430K8656
    US-Symbol: ACST
    Typ: Aktie

    Acasti Pharma News

    10.07.23 - PR Newswire
    Acasti Announces WuXi Clinical as CRO to Conduct STRIVE-ON Pivotal Phase 3 Safety Trial for GTX-104 in aSAH Patients
    Acasti Announces WuXi Clinical as CRO to Conduct STRIVE-ON Pivotal Phase 3 Safety Trial for GTX-104 in aSAH Patients PR Newswire
    07.07.23 - PR Newswire
    Acasti Pharma Announces 1-for-6 Reverse Stock Split
    Acasti Pharma Announces 1-for-6 Reverse Stock Split PR Newswire
    05.07.23 - PR Newswire
    Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023
    Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023 PR ...
    23.06.23 - PR Newswire
    Acasti Pharma Reports Fiscal Year 2023 Operational Results
    Acasti Pharma Reports Fiscal Year 2023 Operational Results PR Newswire
    22.06.23 - PR Newswire
    Acasti Announces Appointment of New Scientific Advisory Board Members
    Acasti Announces Appointment of New Scientific Advisory Board Members PR Newswire
    08.05.23 - PR Newswire
    Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025
    Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through ...
    04.04.23 - PR Newswire
    Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the IND
    Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the IND PR Newswire
    04.04.23 - PR Newswire
    Acasti Announces Appointment of Prashant Kohli as CEO
    Acasti Announces Appointment of Prashant Kohli as CEO PR Newswire
    30.03.23 - PR Newswire
    Acasti Pharma Inc. Announces the Resignation of a Director
    Acasti Pharma Inc. Announces the Resignation of a Director PR Newswire
    13.03.23 - PR Newswire
    Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange
    Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange PR Newswire
    08.03.23 - PR Newswire
    Acasti Pharma to Participate in Oppenheimer 33rd Annual Healthcare Conference
    Acasti Pharma to Participate in Oppenheimer 33rd Annual Healthcare Conference PR Newswire
    28.02.23 - PR Newswire
    Acasti Pharma Recognizes Rare Disease Day
    Acasti Pharma Recognizes Rare Disease Day PR Newswire
    07.02.23 - PR Newswire
    Acasti Pharma to Report Third Quarter 2023 Financial Results on Tuesday, February 14, 2023
    Acasti Pharma to Report Third Quarter 2023 Financial Results on Tuesday, February 14, 2023 PR Newswire
    28.12.22 - PR Newswire
    Thinking about buying stock in Minerva Surgical, IQIYI, Cosmos Health, Acasti Pharma, or AMC Entertainment?
    Thinking about buying stock in Minerva Surgical, IQIYI, Cosmos Health, Acasti Pharma, or AMC Entertainment? PR Newswire
    22.12.22 - PR Newswire
    Thinking about buying stock in Thermogenesis Holdings, ProQR Therapeutics, Grom Social, ORIC Pharmaceuticals, or Acasti Pharma?
    Thinking about buying stock in Thermogenesis Holdings, ProQR Therapeutics, Grom Social, ORIC Pharmaceuticals, or Acasti Pharma? PR Newswire
    23.05.22 - PR Newswire
    Acasti Pharma Inc. Retains Lytham Partners to Lead Strategic Investor Relations and Shareholder Communication Program
    Acasti Pharma Inc. Retains Lytham Partners to Lead Strategic Investor Relations and Shareholder Communication Program PR Newswire
    16.05.22 - ACCESSWIRE
    Update: Acasti Pharma CEO to Present at Microcap Rodeo’s Spring into Action Best Ideas Virtual Conference on May 18th
    LAVAL, QC / ACCESSWIRE / May 16, 2022 / Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq:ACST) and (TSX-V:ACST), today announced that Jan D'Alvise, Chief Executive ...
    12.05.22 - ACCESSWIRE
    Acasti Pharma CEO to Present at Microcap Rodeo's Spring into Action Best Ideas Virtual Conference on May 16th
    LAVAL, QC / ACCESSWIRE / May 12, 2022 / Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ:ACST)(TSXV:ACST), today announced that Jan D'Alvise, Chief Executive Officer, ...
    23.12.21 - PR Newswire
    Thinking about buying stock in SeaChange International, American Virtual Cloud Technologies, Quoin Pharmaceuticals, Acasti Pharma, or CohBar?
    Thinking about buying stock in SeaChange International, American Virtual Cloud Technologies, Quoin Pharmaceuticals, Acasti Pharma, or CohBar? PR Newswire
    22.12.21 - PR Newswire
    Thinking about buying stock in Naked Brand, Biondvax Pharmaceuticals, eMagin Corp, Red Cat, or Acasti Pharma?
    Thinking about buying stock in Naked Brand, Biondvax Pharmaceuticals, eMagin Corp, Red Cat, or Acasti Pharma? PR Newswire

    Newssuche

    Videos

    newspaper
    09:30 Uhr +19,51%
    Technical Trading: S&P 500 Short Chance
    S&P 500 Short Typ: Turbo Open End WKN: NG8FUZ Hebel: 31 Laufzeit: OpenEnd Einstieg: Market ... Mehr »